Synta Pharma up 26% premarket

Shares of Synta Pharmaceuticals (SNTA) are up big premarket in response to the company's report of encouraging results from the ENCHANT-1 ganetespib phase 2 clinical trial for metastatic breast cancer.

Six of seven patients in the HER+2 cohort and 18 of 31 patients in the TNBC cohort achieved a metabolic responses.

Shares are down 60% since the February 2013 high of $11.88. The CEO recently resigned and some analysts have turned bearish.

Watch for upgrades in the next several weeks as analysts wait for the end of an up move before publishing their opinions.

From other sites
Comments (2)
  • kiryxa77
    , contributor
    Comments (23) | Send Message
    Most price targets for this company over $20 for was a great buying opportunity for 4.30$ . The only thing I regret I didn't have enough money to buy more. Long SNTA.
    20 Mar 2014, 09:21 AM Reply Like
  • joelkatz
    , contributor
    Comments (570) | Send Message
    Yahoo has it at $13.83, which is good enough
    20 Mar 2014, 09:28 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs